Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses

Journal of Virology

Volumn 85, Issue 9, 2011, Pages 4618-4622

  McMahon, Moira A ^a   Parsons, Teresa L ^a   Shen, Lin ^a   Siliciano, Janet D ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; LYMPHOBLAST; NONHUMAN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; VIRUS DETECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HERPESVIRIDAE; HIV-1; HUMANS; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955389930     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02423-10     Document Type: Article

References (36)

1. Ansari, A., and V. C. Emery. 1999. The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses. J. Virol. 73:3284-3291.
2. Boutolleau, D., et al. 2005. Detection of human herpesvirus 7 DNA in peripheral blood reflects mainly CD4+ cell count in patients infected with HIV. J. Med. Virol. 76:223-228.
3. Celum, C, et al. 2008. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371:2109-2119.
4. Celum, C, et al. 2010. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N. Engl. J. Med. 362:427-439.
5. Clark, D. A., M. L. Freeland, L. K. Mackie, R. F. Jarrett, and D. E. Onions. 1993. Prevalence of antibody to human herpesvirus 7 by age. J. Infect. Dis. 168:251-252.
6. Corey, L., A. Wald, C. L. Celum, and T. C. Quinn. 2004. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35:435-445.
7. Datta, A. K., and J. S. Pagano. 1983. Phosphorylation of acyclovir in vitro in activated Burkitt somatic cell hybrids. Antimicrob. Agents Chemother. 24: 10-14.
8. De Clercq, E., et al. 2001. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev. Med. Virol. 11:381-395.
9. Elion, G. B., et al. 1977. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U. S. A. 74:5716-5720.
10. Golden, M. P., et al. 1992. Activation of human immunodeficiency virus by herpes simplex virus. J. Infect. Dis. 166:494-499.
11. Hall, C. B., et al. 1994. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N. Engl. J. Med. 331:432-438.
12. Keller, P. M., et al. 1981. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem. Pharmacol. 30:3071-3077.
13. Keller, P. M., S. A. McKee, and J. A. Fyfe. 1985. Cytoplasmic 5'-nucleotidase catalyzes acyclovir phosphorylation. J. Biol. Chem. 260:8664-8667.
14. Kim, H. N., et al. 2010. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J. Infect. Dis. 202:734-738.
15. Krone, M. R., et al. 2000. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. Clin. Infect. Dis. 30:261-267.
16. Levy, J. A., F. Ferro, D. Greenspan, and E. T. Lennette. 1990. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 335:1047-1050.
17. Lisco, A., et al. 2008. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 4:260-270.
18. Margolis, D. M., A. B. Rabson, S. E. Straus, and J. M. Ostrove. 1992. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 186:788-791.
19. McMahon, M. A., et al. 2007. The HBV drug entecavir-effects on HIV-1 replication and resistance. N. Engl. J. Med. 356:2614-2621.
20. McMahon, M. A., J. D. Siliciano, R. M. Kohli, and R. F. Siliciano. 2010. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 24:319-323.
21. McMahon, M. A., et al. 2008. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J. Biol. Chem. 283:31289-31293.
22. Mellors, J. W., et al. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
23. Mosca, J. D., et al. 1987. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc. Natl. Acad. Sci. U. S. A. 84:7408-7412.
24. Nagot, N., et al. 2007. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356:790-799.
25. Neyts, J., G. Andrei, and E. De Clercq. 1998. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42:216-222.
26. Nimmesgern, E., T. Fox, M. A. Fleming, and J. A. Thomson. 1996. Conformational changes and stabilization of inosine 5'-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid. J. Biol. Chem. 271:19421-19427.
27. Reardon, J. E. 1989. Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition. J. Biol. Chem. 264: 19039-19044.
28. Reardon, J. E., and T. Spector. 1989. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 264:7405-7411.
29. Schacker, T., et al. 1998. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann. Intern. Med. 128:21-28.
30. Schacker, T., J. Zeh, H. Hu, M. Shaughnessy, and L. Corey. 2002. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J. Infect. Dis. 186:1718-1725.
31. Shen, L., et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766.
32. Smee, D. F., R. Boehme, M. Chernow, B. P. Binko, and T. R. Matthews. 1985. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihy-droxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem. Pharmacol. 34:1049-1056.
33. Watson-Jones, D., et al. 2008. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N. Engl. J. Med. 358:1560-1571.
34. Weller, S., et al. 1993. Pharmacokinetics of the acyclovir pro-drug valaciclo-vir after escalating single and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:595-605.
35. Zhang, H., et al. 2004. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78:1718-1729.
36. Zuckerman, R. A., et al. 2007. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J. Infect. Dis. 196:1500-1508.